TrialStudy to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
Trial details
- Registry ID
- NCT03459287
- Phase
- Phase 3
Drug research
Control
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity has not yet been verified against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery PatientsNCT03459287 | Cerus Corporation | Phase 3 | Completed | 2023-12-04Actual |
| Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid LeukemiaNCT04571645 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2022-05-16Actual |
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
Trial details
- Registry ID
- NCT04571645
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |